Skip to content

Telemedicine Approaches to Evaluating Acute-phase ROP

Telemedicine Approaches to Evaluating Acute-phase ROP

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01264276
Acronym
e-ROP
Enrollment
269
Registered
2010-12-21
Start date
2011-07-31
Completion date
2014-01-31
Last updated
2015-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematurity

Keywords

ROP, Retinopathy of Prematurity, Telemedicine

Brief summary

The primary objective of this multi-center clinical study is to evaluate the validity, reliability, feasibility, safety and relative cost-effectiveness of a retinopathy of prematurity (ROP) telemedicine evaluation system to detect eyes of at-risk babies who meet referral warranted ROP (RW-ROP) criteria and therefore need a diagnostic evaluation by an ophthalmologist experienced in ROP. We shall: 1. Calculate the accuracy, using sensitivity and specificity, of the system to provide remote evaluations when compared with the findings of a gold standard indirect ophthalmoscopic examination performed by a Study-certified ophthalmologist, rigorously trained in ROP diagnostic examinations (validity); 2. Determine intra-reader and inter-reader agreement for deciding whether digital images indicate that the eyes of a baby are in need of diagnostic indirect ophthalmoscopy by an ophthalmologist experienced in ROP (reliability); 3. Determine whether imaging evaluation can be achieved for each baby (feasibility); 4. Examine ocular and systemic complications associated with digital imaging and compared with those associated with diagnostic examinations performed by an ophthalmologist (safety); 5. Compare the costs and benefits of adopting a telemedicine retinal imaging system compared to the current cost of indirect ophthalmoscopic examinations (cost-effectiveness).

Detailed description

Eligibility Criteria: • Babies with birth weights of \<1251 grams(g) at selected large clinical centers in the US and Canada. Procedures: • Participants will undergo both digital retinal imaging and clinically indicated indirect ophthalmoscopic examinations on the same day. Wide-field digital images (WF-DI) of both eyes will be captured by non-physician Certified ROP Imagers (CRIs) using standardized imaging protocols. The RetCam Shuttle® (Clarity Medical Systems, Pleasanton, CA), a corneal-contact camera that captures wide field (130 degree field of view) retinal images, will be used. Masking: • Study-certified Ophthalmologist and Study-certified Imager at the clinical sites will be masked to each other's findings. The Study Clinical Coordinator (SCC) will remain unmasked. SCC will monitor the clinical noteworthy events and report all adverse events to the site Institutional Review Board (IRB), the Project Director at the Office of Study Chair, and to the Data Coordinating Center (DCC). DCC will prepare closed-session Data Monitoring and Oversight Committee (DMOC) reports. The PI at each site will monitor adverse events. Outcome Measures: • The primary outcome measure is detection of referral warranted ROP (RW-ROP) on digital images. Retinal images will be graded by Trained Readers using a standardized protocol to identify eyes with RW-ROP. Results of the gradings will be compared to the diagnostic examinations being performed on each child at the same session when images taken. For comparison, images will also be graded by ROP experts (Expert Readers).

Interventions

None listed

Sponsors

Johns Hopkins University
CollaboratorOTHER
Boston Children's Hospital
CollaboratorOTHER
Nationwide Children's Hospital
CollaboratorOTHER
Duke University
CollaboratorOTHER
University of Louisville
CollaboratorOTHER
University of Minnesota
CollaboratorOTHER
University of Oklahoma
CollaboratorOTHER
The University of Texas at San Antonio
CollaboratorOTHER
University of Utah
CollaboratorOTHER
University of Pennsylvania
CollaboratorOTHER
Vanderbilt University
CollaboratorOTHER
University of Calgary
CollaboratorOTHER
National Eye Institute (NEI)
CollaboratorNIH
Children's Hospital of Philadelphia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
32 Weeks to 40 Weeks
Healthy volunteers
No

Inclusion criteria

* Babies with birth weighs of \<1251g at selected large clinical centers in the US and Canada. * Admitted to a participating Neonatal Intensive Care Units (NICU) and expected to survive to 28 days. * Likely to remain in participating NICU for serial ROP exams. * Transferred to participating NICU for treatment of ROP (regardless of PMA). * Parents or guardians have provided informed consent for participation in the study.

Exclusion criteria

* Failure to obtain informed consent. * Known ocular anomalies that prevent imaging of the retina. * Life threatening anomalies (i.e. heart, neurological, etc). * Admission to participating NICU with ROP that is already regressing or treated.

Design outcomes

Primary

MeasureTime frame
Detection of Referral Warranted ROP6 weeks

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026